Clinical trials: Human Papilloma Virus
Human Papillomavirus (HPV) Infection, HPV Vaccination Acceptance/Intention
Effect of Different HPV Education Methods on Vaccination Intention in Young Women
Detailed Description Human papillomavirus (HPV) is one of the leading causes of cervical cancer and can be prevented by vaccination.
- Trial name
- NCT07420556
- Testing
- Video-Based HPV Education, Face-to-Face HPV Education
- Where
- Turkey (Türkiye)
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Emel GÜÇLÜ CİHAN
HPV Infection, CIN1
Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions
A Phase 1b/2 multi-centre study evaluating the safety, efficacy and immunogenicity of prime-boost vaccines ChAdOx1-HPV and MVA-HPV in women with HPV related low grade cervical lesions.
- Trial name
- NCT04607850
- Testing
- ChAdOx1-HPV, MVA-HPV
- Where
- 16 sites in Belgium, Estonia and 1 more
- Volunteers
- 108 people
- Sponsor
- Barinthus Biotherapeutics
Cervical Cancer Screening
Reengineering Cervical Cancer Screening for the 21st Century: Joint Action for a Novel Up-to-date and Sustainable Screening Program
Cervical cancer screening (CCS) is important to prevent and control cervical cancer (CC). In Portugal, CCS starts with the assessment of the presence of Human Papillomavirus (HPV) in cervical-vaginal samples, collected by a…
- Trial name
- JANUS (NCT06915610)
- Testing
- Invitation of all participants to CCS according to the standard of care (active comparator), Invitation of all participants to CCS through self-sampling, Invitation of all participants to CCS, asking them to choose between self-sampling and the standard of care
- Where
- Portugal
- Volunteers
- 5,700 people, healthy volunteers welcome
- Sponsor
- Instituto de Saude Publica da Universidade do Porto
Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
The goal of this clinical study is to learn if DARE-HPV can treat persistent high-risk human papillomavirus (hrHPV). The primary outcome will be if the genital infection clears following treatment in 30, 60 or 90 days.
- Trial name
- NCT07601074
- Testing
- Lopinavir / ritonavir
- Where
- 10 sites in United States
- Volunteers
- 118 people
- Sponsor
- Daré Bioscience, Inc.
HPV Genital Infection (Primary Condition Studied), Bacterial Vaginosis
Kinetics and Ecology of Human Papillomavirus Genital Infections in Young Women
Most genital infections by human papillomaviruses (HPV) are asymptomatic or benign and clear within a few months or years. There infections are much less studies than chronic infections, even though they represent the main…
- Conditions
- HPV Genital Infection (Primary Condition Studied), Bacterial Vaginosis, Chlamydiae Infection
- Trial name
- PAPCLEAR (NCT02946346)
- Testing
- vaginal sampling
- Where
- France
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Cancer of the Uterine Cervix
Feasibility and Acceptability of Offering Self-sampling to Non-attendees in Primary Care
The purpose of this study is to determine whether human-papillomavirus (HPV) self-sampling can be used as a primary screening test for unscreened women.
- Trial name
- DEPIST (NCT02698423)
- Testing
- Cobas HPV DNA Test, Papanicolau test
- Volunteers
- 667 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
Solid Tumors, Adult, PIK3CA Mutation-Related Tumors
Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma
This phase I/II trial tests the safety, side effects, and best dose of alpelisib and whether alpelisib and carboplatin work to shrink tumors in patients with solid tumors or human papillomavirus (HPV) positive squamous cell…
- Conditions
- Solid Tumors, Adult, PIK3CA Mutation-Related Tumors, PIK3CA Mutation, Human Papillomavirus-Related Carcinoma
- Trial name
- NCT05472220
- Testing
- Alpelisib, Carboplatin, Hyperpolarized Carbon-13 (13C) Pyruvate
- Sponsor
- Pamela Munster
Warts, Genital, Neoplasms, Anal
Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064)
The purposes of this phase 3, double-blind, placebo-controlled clinical study are to evaluate the efficacy of V503 in preventing human papillomavirus (HPV)-related anogenital persistent infection, and to evaluate the…
- Trial name
- NCT04635423
- Testing
- V503
- Where
- 22 sites in Japan
- Volunteers
- 1,059 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Papillomavirus Infections, Dysplasia
Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix
This study aims to compare the expression of matrix metalloproteinases and their tissue inhibitors between 4 groups of patients defined according to the severity of the cervical lesion.
- Conditions
- Papillomavirus Infections, Dysplasia, Cervix Cancer
- Trial name
- MMP-HPV (NCT04072913)
- Testing
- Vaginal samples (biopsies + vaginal smear)
- Where
- France
- Volunteers
- 216 people
- Sponsor
- University Hospital, Bordeaux
Cervical Intraepithelial Neoplasia
A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study
The purpose of this study is to evaluate the persistence of immune response in subjects who received the HPV-16/18 vaccine, seven to eight years after the last dose of primary vaccination in the HPV-058 study.
- Trial name
- NCT03355820
- Testing
- Blood sampling for antibody determination
- Where
- China
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Recurrent Respiratory Papillomatosis
Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis
The purpose of this study is to determine if administration of the HPV quadrivalent vaccine in patients diagnosed with RRP has a therapeutic effect on their clinical course.
- Trial name
- NCT00829608
- Testing
- Human Papillomavirus Vaccine
- Where
- United States
- Sponsor
- University of Missouri-Columbia
High-grade Squamous Intraepithelial Lesions of the Cervix Associated With Human Papillomavirus (HPV) Type 16 and/or HPV Type 18 Infection
Evaluation of the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade Squamous Intraepithelial Lesion(HSIL)
The goal of this study is to learn about the safety, tolerability, immunogenicity and preliminary efficacy of BBM-C101 injection in patients with High-Grade Squamous Intraepithelial Lesion of the cervix.
- Trial name
- NCT07668960
- Testing
- BBM-C101
- Where
- 4 sites in China
- Volunteers
- 60 people
- Sponsor
- Shanghai Mianyi Biopharmaceutical Co., Ltd.
Cervical Cancer, Cervical Intraepithelial
Cervical Cancer Early Endpoints and Determinants
This study, conducted by the National Cancer Institute and the University of Oklahoma, will look for changes in cervix cells and other samples that may be signs of cervical disease.
- Conditions
- Cervical Cancer, Cervical Intraepithelial, Neoplasia, CIN
- Trial name
- NCT00339989
- Where
- United States
- Volunteers
- 3,013 people
- Sponsor
- National Cancer Institute (NCI)
Common Warts, Common Warts (Verruca Vulgaris)
Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5)
This is a Phase 2, open-label study (Study VP-CW-304; referred to as COVE-5 [Cantharidin and Occlusion in Verruca Epithelium 5]) to evaluate the safety and systemic exposure of YCANTH (VP-102) following a single 24-hour dermal…
- Conditions
- Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
- Trial name
- COVE-5 (NCT07881952)
- Testing
- VP-102
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Transgenderism, Cervical Cancer
Implementing HPV DNA Self-Collection to Increase Rates of Cervical Cancer Screening in Transgender Men
Transgender men are individuals born genetically female that have a gender identity that is incongruent with their biological sex.
- Conditions
- Transgenderism, Cervical Cancer, Human Papilloma Virus
- Trial name
- NCT04154358
- Testing
- HPV testing
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Augusta University
Human Papillomavirus Infection, Human Immunodeficiency Virus Infection
HPV Infection, Sexually Transmitted Infections and Anal Dysplasia in the Transgender Population
The goal of this observational study is to estimate the prevalence of HPV infections anal and ENT level and according to HIV status in transgender (TG) population.
- Conditions
- Human Papillomavirus Infection, Human Immunodeficiency Virus Infection, Sexually Transmitted Diseases
- Trial name
- PrevHPV-TG (NCT05981807)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Human Papillomavirus, Human Papillomavirus Infection
Human Papillomavirus in Young People Epidemiological Research 2 (HYPER2)
Australia was one of the countries to implement a universal school-based male vaccination program - in 2013. This research project will examine the prevalence of HPV among young men who have sex with men (MSM) who have been…
- Trial name
- HYPER2 (NCT03000933)
- Where
- Australia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- The Alfred
Human Papillomavirus Vaccination, Cervical Cancer Prevention
Integrating HPV Education Into School Health Programs in Cambodia and Kenya
The Clinton Health Access Initiative conducted a mixed-methods, school-based interventional study in Cambodia and Kenya to evaluate whether integrating age-appropriate human papillomavirus (HPV) education into existing school…
- Trial name
- NCT07784283
- Testing
- Integrated HPV Education
- Where
- 5 sites in Cambodia, Kenya
- Volunteers
- 9,054 people, healthy volunteers welcome
- Sponsor
- Clinton Health Access Initiative Inc.
Cervix Cancer, Human Papilloma Virus
Relational Agents in Cervical Cancer Education (RACE)
The goal of this clinical trial is to assess the feasibility of using interactive teaching to educate cervical cancer patients about Human papillomavirus (HPV) and HPV vaccinations.
- Conditions
- Cervix Cancer, Human Papilloma Virus, Vaginal Cancer, Vulvar Cancer
- Trial name
- RACE (NCT06537687)
- Testing
- Control, Intervention
- Where
- 2 sites in United States
- Volunteers
- 91 people
- Sponsor
- Radhika Gogoi
Papillomavirus Infections
A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)
This study will evaluate whether co-administration of the first dose of V503 and REPEVAX™ is well tolerated and causes a non-inferior immune response when compared to administration of REPEVAX™ one month following the first dose…
- Trial name
- NCT01073293
- Testing
- V503 Vaccine, REPEVAX™ (Concomitant), REPEVAX™ (Non-concomitant)
- Volunteers
- 1,054 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC